

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	D.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/731,968	_	12/09/2003	John Kantor	P1229 US	6422
28390	7590	05/27/2005	EX		AMINER
		SCULAR, INC.	SNOW, BRUCE EDWARD		
IP LEGAL DEPARTMENT 3576 UNOCAL PLACE				ART UNIT	PAPER NUMBER
SANTA R	OSA, CA	95403	3738		
				DATE MAILED: 05/27/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Commence	10/731,968	KANTOR, JOHN
Office Action Summary	Examiner	Art Unit
TI MANUA DATE A Abia	Bruce E Snow	3738
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be timed within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).
Status		
 1) Responsive to communication(s) filed on 15 M 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowar closed in accordance with the practice under E 	action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-31 is/are pending in the application. 4a) Of the above claim(s) 6,8,18 and 24 is/are s 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-5, 7, 9-17, 19-23, 25-31 is/are reject 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	withdrawn from consideration.	
Application Papers		·
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct and the option of the op	epted or b) objected to by the ld drawing(s) be held in abeyance. Sec ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) \[\sum \] Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)
Notice of References Cited (PTO-992) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail D	

Art Unit: 3738

DETAILED ACTION

Page 2

Response to Arguments

Applicant's arguments filed 3/15/05 have been fully considered, however, applicant's arguments regarding the rejection in view of Pinchuk et al are not persuasive. Applicant argues, "[a]pplicant respectfully asserts that the language the Examiner uses to describe the Pinchuk stent, "a first plurality of zig-zags 34" and "a second plurality of zig-zags 36" is not used in the Pinchuk patent and does not describe the Pinchuk stent." The Examiner notes that Pinchuk might not use that specific language, however, it is the Examiner's interpretation of Pinchuk that a stent module comprises a first plurality of zig-zags 34, and more narrowly, the plurality of zig-zags forms approximately one turn; each approximate turn is a "module".

Regarding claim 25 requiring a radiopaque material, Pinchuk et al teaches adding radioactive materials containing beta or gamma emitters which can be seen by an x-ray.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-5, 7, 9-17, 19-23, 25-31 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to

Art Unit: 3738

reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Page 3

Claims 1, 17, 19, 28, have been amended to include the language, "such that the lateral and longitudinal stability is improved" which is new matter. Applicant's arguments, page 13, read, "[s]upport for these amendments can be found in paragraph 0029. No new matter was added as a result of the amendments to claims 1, 17, 19, and 28". This language was not found by the Examiner only a description of the flexibility.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical

Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting

Application/Control Number: 10/731,968

Art Unit: 3738

directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1-5, 7, 9-17, 19-23, 25-31 are rejected under 35 U.S.C. 102(b) as being anticipated by Pinchuk et al (5,968,091).

Referring to figure 7, Pinchuk et al teaches a modular stent comprising:

A first stent module (a first plurality of zig-zags 34 (forming an approximate turn)) defining a first passageway;

At least a second stent module (a second plurality of zig-zags 36 (forming an approximate turn) adjacent to the first) defining a second passageway; and

At least one polymer bridge in communication with the first and second stent module, said bridge coupling said first and second module. See at least figure 7 and column 3, lines 20 et seq. teaching a polymeric coating and types of polymers over most of the stent including internal and external surfaces.

Regarding at least claim 7 requiring a polymer hinge defining a gap, see column 2, lines 60-63, teaching the modules can touch or not touch (producing a gap).

Regarding the therapeutic agent, see column 4, lines 18 et seq.

Regarding at least claim 13, see column 4, lines 28 et seg.

Regarding claim 15, module is porous, see drug eluting reservoirs.

Regarding claim 16, module is non-porous, the materials for the stent are non-porous.

Regarding claim 25, see at least column 7, lines 60 et seq.

Regarding the independent claims, it is the Examiner's position that the bridge of Pinchuk et al fulfills the functional language "such that the lateral and longitudinal stability is improved".

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruce E Snow whose telephone number is (571) 272-4759. The examiner can normally be reached on Mon-Thurs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone

Application/Control Number: 10/731,968 Page 6

Art Unit: 3738

number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

bes

BRUCE SNOW PRIMARY EXAMINER